Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

This study tests whether a drug called daratumumab can eliminate residual leukemia cells in people with T-cell acute lymphoblastic leukemia (T-cell ALL) who are in remission but still have detectable cancer cells (called minimal residual disease, or MRD) after intensive chemotherapy. **You may be eligible if...** - You have been diagnosed with T-cell ALL - You are currently in blood cancer remission (complete or near-complete) after at least 2 cycles of intensive chemotherapy - You still have detectable cancer cells at a very small level (MRD ≥ 1 in 10,000 cells) confirmed by a central lab test - You are in reasonably good general health - If you had a prior bone marrow transplant, you do not have active graft-versus-host disease requiring immune suppression (other than low-dose prednisone) **You may NOT be eligible if...** - Your T-cell ALL is not confirmed - You are not in remission - MRD has not been confirmed by a central lab - You have active graft-versus-host disease requiring significant immune-suppressing medications Talk to your doctor to see if this trial is right for you.